Vericel to Report First-Quarter 2019 Financial Results on May 7, 2019
25 Abril 2019 - 09:30AM
Vericel Corporation (NASDAQ:VCEL), a leader in advanced cell
therapies for the sports medicine and severe burn care markets,
today announced the following webcast and conference call to
discuss its first-quarter 2019 financial results and business
highlights.
What: |
Vericel Corporation First-Quarter 2019 Earnings Call |
When: |
Tuesday, May 7, 2019 at 8:00am (EDT) |
Where: |
http://investors.vcel.com/events-presentations |
How: |
The conference call will be available live in the
Investors section of the Vericel website at
http://investors.vcel.com/events-presentations. Please access the
site at least 15 minutes prior to the scheduled start time in order
to download the required audio software if necessary. |
To participate in the live call by telephone, please call (877)
312-5881 and reference Vericel Corporation first-quarter 2019
earnings call. If calling from outside the U.S., please use the
international phone number (253) 237-1173.
If you are unable to participate in the live call, the webcast
will be available at http://investors.vcel.com/events-presentations
until May 7, 2020. A replay of the call will also be available
until 11:30am (EDT) on May 12, 2019 by calling (855) 859-2056, or
from outside the U.S. (404) 537-3406. The conference ID is
1775796.
About Vericel CorporationVericel is a leader in
advanced cell therapies for the sports medicine and severe burn
care markets. The company markets two cell therapy products in the
United States. MACI® (autologous cultured chondrocytes on porcine
collagen membrane) is an autologous cellularized scaffold product
indicated for the repair of symptomatic, single or multiple
full-thickness cartilage defects of the knee with or without bone
involvement in adults. Epicel® (cultured epidermal autografts) is a
permanent skin replacement for the treatment of patients with deep
dermal or full thickness burns greater than or equal to 30% of
total body surface area. For more information, please visit the
company's website at www.vcel.com.
Epicel® and MACI® are registered trademarks of Vericel
Corporation. © 2019 Vericel Corporation. All rights reserved.
Global Media Contacts:David SchullRusso
Partners LLCDavid.schull@russopartnersllc.com +1 212-845-4271
(office)+1 858-717-2310 (mobile)
Karen ChaseRusso Partners
LLCKaren.chase@russopartnersllc.com +1 646-942-5627 (office)+1
917-547-0434 (mobile)
Investor Contacts: Chad RubinSolebury
Troutcrubin@troutgroup.com +1 646-378-2947
Lee SternSolebury Troutlstern@troutgroup.com +1
646-378-2922
Vericel (NASDAQ:VCEL)
Gráfico Histórico do Ativo
De Fev 2024 até Mar 2024
Vericel (NASDAQ:VCEL)
Gráfico Histórico do Ativo
De Mar 2023 até Mar 2024